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Objectives: Data on macrovascular involvement in systemic sclerosis (SSc) are still 
debatable. The aim of this study was to estimate its prevalence and possible deter-
minants in a large cohort.
Methods: One hundred and fifty-five outpatients with SSc were enrolled. Data about 
disease characteristics and cardiovascular risk factors were collected and patients 
underwent ecocolor Doppler ultrasonography of arteries of the neck and lower (LL) 
and upper (UL) limbs.
Results: Mean age was 57.9 ± 14.5 years and most were female (88.4%) with a limited 
subset (63.2%). Mean disease duration was 11.4 ± 8.1 years. Twenty-three (14.8%) 
had hypertension, 7 (4.8%) diabetes, 64 (41.3%) hypercholesterolemia and 63 (40.6%) 
were active/past smokers. Seventy-nine (49%) patients had plaques at carotids, 49 
(32.9%) at LL and 7 (4.9%) at UL. In multivariate analysis, patients with carotid plaques 
had more often a limited pattern (P = .001), patients with distal LL plaques pulmonary 
arterial hypertension (P = .006) and patients with proximal LL plaques lower diffus-
ing capacity for carbon monoxide adjusted to hemoglobin and its ratio to alveolar 
volume (P = .004). In patients with UL plaques traditional cardiovascular risk factors 
were not more common, while forced vital capacity was lower (P = .023). Finally, 
upper limb and proximal LL plaques were as common in early disease patients as in 
longstanding ones, although the former were younger.
Conclusions: This study shows that macrovascular involvement is quite common in 
SSc and that some disease characteristics linked to microvascular involvement are 
associated with atherosclerotic plaques, which can be present even in early disease. 
Our study suggests that a complete evaluation of macrocirculation is mandatory for 
rheumatologists treating SSc patients.
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1  | INTRODUC TION
Skin and visceral microvasculopathy is a typical characteristic of sys-
temic sclerosis (SSc), together with abnormal widespread deposition of 
collagen and other proteins of extracellular matrix, as shown by some 
threatening and severe clinical manifestations such as digital ulcers, 
pulmonary artery hypertension (PAH) and scleroderma renal crisis.1,2
Whether macrovasculopathy affects scleroderma patients has 
been the object of some studies leading to contrasting results. A 
possible reason is the great heterogeneity between studies, as un-
derlined by a meta-analysis published in 2011.3 The same paper 
showed that carotid intima-media thickness (cIMT) was found higher 
in SSc than controls in 6 out of 14 studies.3 In those showing higher 
cIMT, differences with controls were found comparable to those 
shown in other diseases characterized by an increased cardiovas-
cular risk such as rheumatoid arthritis (0.09 mm),4 diabetes mellitus 
(0.13 mm)5 and familial hypercholesterolemia (0.12 mm),6 so the 
burden of carotid atherosclerosis in SSc may be of some relevance, 
although still debatable.
Also, data on peripheral artery disease at lower limbs (LL) were 
discordant. Ho et al7 found evidence of atherosclerosis in 9 out of 53 
SSc cases (17%) compared with no controls, whereas Bartoli et al8 
and Nordin et al9 did not show any difference in ankle-brachial pres-
sure index (ABPI) between patients and healthy subjects.
Some studies underlined the involvement of ulnar artery in SSc. 
In previous studies, Doppler examination showed that the diame-
ter of ulnar artery was narrower in 20 SSc patients compared to 20 
controls10 and an occlusion of ulnar artery was found in 17 out of 79 
SSc patients.11
The aim of the present study was to assess macrovascular in-
volvement in a large and well-defined cohort of SSc patients by con-
temporaneously evaluating, by Doppler ultrasonography, 3 different 
arterial districts, that is carotid arteries and arteries of upper limbs 
(UL) and LL; in addition, we evaluated a great number of clinical fea-
tures in order to study if any of them may be useful to select those 
SSc patients at increased atherosclerotic risk.
2  | PATIENTS AND METHODS
For the present study we enrolled 155 consecutive outpatients 
affected by SSc followed at the Rheumatology Unit of Verona, 
Roma and Modena. All patients fulfilled the American College of 
Rheumatology/European League Against Rheumatism classification 
criteria for SSc.12 The distinction between limited and diffuse cu-
taneous SSc was made according to LeRoy et al13 criteria. Skin in-
volvement was assessed by modified Rodnan skin score (mRSS).14 
Antinuclear antibodies (ANA) and anticentromere antibodies (ACA) 
were tested by indirect immunofluorescence on HEp-2 cells, and 
anti-Scl70 antibodies were searched by enzyme-linked immunosorb-
ent assay method.
Laboratory evaluation also included erythrocyte sedimenta-
tion rate (ESR), C-reactive protein (CRP), creatinine with estimated 
glomerular filtration rate (eGFR), total, high density lipoprotein (HDL) 
and low density lipoprotein (LDL) cholesterol, triglycerides, glucose 
and homocysteine levels. Each patient underwent pulmonary func-
tion tests with diffusing capacity for carbon monoxide adjusted to 
hemoglobin (DLCO) and ratio of DLCO to alveolar volume (DLCO/
AV). At the same time body mass index (BMI) was calculated and 
disease severity score was assessed, as proposed by Medsger et al15 
The diagnosis of interstitial lung disease (ILD) and PAH was based 
upon lung high-resolution computed tomography and right heart 
catheterization, respectively. Digital ulcers were defined as ischemic 
ulcers located at the digit tip. Evaluation of the cardiovascular risk 
was made in agreement with the European Low Risk Chart proposed 
by the European Society of Cardiology (ESC),16 which considers the 
following parameters: gender, age, systolic blood pressure, total cho-
lesterol value and smoking habits.
All patients underwent Doppler ultrasonography (DUS) of the 
carotid arteries and of the UL and LL arteries. The following arteries 
were analyzed: common carotid, internal and external carotid, sub-
clavian artery, humeral artery, ulnar artery, radial artery, common 
femoral artery, profunda femoral artery, superficial femoral artery, 
popliteal artery, anterior and posterior tibial artery. cIMT measure-
ments were carried out after a 15-minutes resting interval and no 
intravenous vasodilators were given the day of the examination and 
during the 3 previous days. Patients underwent ultrasound measure-
ment of cIMT at both common carotid arteries on the distal wall. 
cIMT was examined by a skilled operator using a high-resolution 
linear probe (7.5 MHz) by means of automatic ultrasound detection 
of cIMT (Esaote MyLab 30 Gold—QIMT). Common carotids were ex-
amined at standard angles bilaterally: 1 cm proximally to the bulb, a 
segment of 2 cm was selected with the cursor of the system and IMT 
was automatically calculated. Median IMT for each common carotid 
artery was calculated and expressed in centimeters.
Plaques were defined as a localized increase of vessel wall profile 
of more than 1.5 mm. Stenoses were calculated in accordance with 
the Consensus Panel Gray-Scale and Doppler Ultrasound Criteria for 
Diagnosis reported by Grant et al.17
A written informed consent was obtained from all the partici-
pants in the study. The protocol study was approved by the local 
Ethical Committee (protocol no. 55946 for Verona University, proto-
col no. 3822/14 for Catholic University of the Sacred Heart of Rome, 
protocol no. 10693 of 25/05/2016 for Modena and Reggio Emilia 
University).
2.1 | Statistics
Continuous variables were expressed as mean ± standard deviation 
if they were normally distributed and as median with interquartile 
range if they were not normally distributed. Categorical variables 
were expressed as percentage. Comparisons between groups were 
performed using t test, Mann-Whitney or Chi-square tests/Fisher's 
test, as appropriate. The determinants of macrovascular involve-
ment were explored with logistic multivariate regression. Receiver 
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operating characteristic analysis was run to evaluate the perfor-
mance of ESC score in predicting subclinical atherosclerosis. A P 
value < .05 was considered significant. Statistical analysis was per-
formed by SPSS 17.0 (SPSS Inc).
3  | RESULTS
3.1 | SSc cohort
The study population was composed of 155 subjects, 18 male 
and 137 female, of which 95 (69.3%) were in menopause sta-
tus. Mean age was 57.9 ± 14.5 years; the disease duration was 
11.4 ± 8.1 years and the time from onset of Raynaud's phenom-
ena was 16.4 ± 11.7 years. The main clinical characteristics are re-
ported in Table 1.
3.2 | Carotid atherosclerosis
Seventy-five patients (49%) had carotid plaques. The artery stenosis 
was <50% in the majority of subjects (51 cases); 4 and 2 patients 
showed a hemodynamically significant stenosis comprised between 
50% and 60% and between 60% and 70%, respectively. The mean 
value of IMT was 0.09 mm.
In univariate analysis we found the following differences: sclero-
derma patients with plaques were older (P < .001), more frequently 
had a limited cutaneous pattern of disease (P = .030) and hyperten-
sion (P = .032), showed higher values of glucose (P = .005), disease 
severity score (P = .009), homocysteine (P = .014) and ESR (P = .001) 
and lower values of eGFR (P = .002). Current immunosuppressive 
therapy was negatively associated with the presence of carotid 
plaques (P = .017). In terms of autoantibodies, ACAs were more fre-
quent in patients with plaques (58% vs 42%, P = .045). These data 
are shown in Table 2.
TA B L E  1   Demographic and the clinical data of the 155 patients 
affected by systemic sclerosis
Agea  57.9 (14.5)
Disease duration, yb  11.4 (8.1)
Time from onset of Raynaud's phenomenon, ya  16.4 (11.7)
BMI, kg/m2a  24.0 (4.1)
Pack-yearb  0.0 (7.5)
FVC, predicted (%)a  102 (22)
DLCO, predicted (%)a  67 (22)
DLCO/AV, predicted (%)a  74 (22)
mRSSb  7 (7)
Disease severity score (15)b  5 (3)
Creatinine, mg/dLa  0.8 (0.2)
eGFR using CKD-EPI formula, mL/min/1.73 m2a  88 (21)
Total cholesterol, mg/dLa  188 (34)
HDL cholesterol, mg/dLa  60 (18)
LDL cholesterol, mg/dLa  108 (30)
Triglycerides, mg/dLa  103 (46)
Glucose, mg/dLa  85 (14)
Homocysteine, μmol/La  14.5 (7.9)
IMT, cma  0.09 (0.05)
ESR, mm/ha  24 (16)
CRP, mg/Lb  3 (0)






Endothelin receptor antagonistsc  20 (13.2)
Iloprost 143 (92.9)
Current immunosuppressantsc  48 (31.6)
Previous immunosuppressantsc  57 (36.8)
HCQc  31 (20.0)










Active ischemic digital ulcersc  12 (7.7)
Previous ischemic digital ulcersc  48 (31.0)




Blood hypertensionc  23 (14.8)
Diabetes mellitusc  7 (4.8)
Abbreviations: ACA, anticentromere antibodies; ANA, antinuclear 
antibodies; BMI, body mass index; CDK-EPI, Chronic Kidney Disease 
Epidemiology Collaboration; CRP, C-reactive protein; DLCO, diffusion 
lung for carbon monoxide; eGFR, estimated glomerular filtration rate; 
ESC, European Society of Cardiology; ESR, erythrocyte sedimentation 
rate; FVC, forced vital capacity; HCQ, hydroxychloroquine; HDL, high 
density lipoproteins; ILD, interstitial lung disease; IMT, intima-media 
thickness; LDL, low density lipoprotein; mRSS, modified Rodnan skin 
score; PAH, pulmonary artery hypertension; RCS, Raynaud's condition 
score; VA, alveolar volume; VAS, visual analog scale.
aValues expressed as mean (SD). 
bValues expressed as median (interquartile range). 
cValues expressed as absolute number (%). 
TA B L E  1   (Continued)
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TA B L E  2   Differences between patients with plaques at carotid or upper limb arteries and those without
 
Carotid plaques Upper limb plaques
No Yes P No Yes P
Agea  52.2 (14.2) 63.5 (12.3) <.001 60.2 (21.0) 52.5 (26.0) ns
Disease duration, yb  9 (10.3) 12 (9) ns 10.0 (10.0) 14.0 (11.0) ns
BMI, kg/m2a  23.4 (4.1) 24.6 (4.1) 0.067 24.0 (6.1) 20.3 (8.2) ns
FVC, predicted (%)a  103 (21) 100 (24) ns 104 (26) 87 (49) .021
DLCO, predicted (%)a  68 (21) 65 (23) ns 66 (27) 48 (25) .023
DLCO/AV, predicted (%)a  74 (21) 74 (24) ns 77 (29) 56 (43) .022
mRSSb  7 (8) 8 (7) ns 7 (7) 8 (11) ns
Disease severity score, 15b  5 (2.5) 6 (4) .009 5 (3) p .043
Creatinine, mg/dLa  0.7 (0.1) 0.8 (0.3) ns 0.72 (0.19) 0.63 (0.2) ns
eGFR using CKD-EPI formula, mL/
min/1.73 m2a 
95 (20) 82 (20) .002 89 (18)  ns
Total cholesterol, mg/dLa  189 (36) 186 (33) ns 187 (44) 177 (37) ns
HDL cholesterol, mg/dLa  61 (20) 59 (15) ns 58 (21) 52 (20) ns
LDL cholesterol, mg/dLa  109 (30) 107 (31) ns 104 (43) 95 (23) ns
Triglycerides, mg/dLa  98 (32) 107 (53) ns 93 (56) 77 (64) ns
Glucose, mg/dLa  82 (13) 88 (14) .005 84 (16) 88 (39) ns
Homocysteine, μmol/La  12.8 (6.4) 16.4 (8.8) .014 12.4 (6.4) 9.8 (–) ns
ESR, mm/ha  19 (13) 28 (17) .001 18 (22) 35 (46) ns
CRP, mg/Lb  3 (1) 3 (1) ns 3.0 (0.0) 2.0 (4.6) ns
ESC scoreb  1 (2) 2 (1) .054 1 (2.0)  ns
Femalec  73 (93.6) 63 (84.0) .059 126 (88.1) 7 (100.0) ns
Smokerc 
Never 50 (64.1) 42 (56.0) ns 86 (60.1) 4 (57.1) ns
Previous 20 (25.6) 26 (34.7) 43 (30.1) 2 (28.6)
Active 8 (10.3) 7 (9.3) 14 (9.8) 1 (14.3)
Endothelin receptor antagonistsc  11 (14.5) 9 (12.0) ns 17 (11.9) 3 (42.9) .050
Iloprost 72 (93.5) 69 (92.0) ns 132 (93.0) 7 (100.0) ns
Current immunosuppressantsc  31 (40.8) 17 (22.7) .017 46 (67.8) 5 (71.4) ns
Previous immunosuppressantsc  32 (41.0) 24 (32.0) ns 53 (37.1) 3 (42.9) ns
HCQc  16 (20.5) 15 (20.0) ns 30 (21.0) 0 (0.0) ns
Current steroid treatment 12 (15.8) 18 (24.0) ns 28 (19.6) 1 (14.3) ns
Autoantibodiesc 
Scl70 34 (43.6) 24 (32.0) ns 53 (37.1) 4 (57.1) ns
ACA 29 (37.2) 40 (53.3) ns 65 (45.5) 2 (28.6)
ANA 15 (19.2) 11 (14.7) ns 25 (17.5) 1 (14.3)
Cutaneous patternc 
Limited 43 (55.1) 54 (72.0) .030 91 (63.6) 4 (57.1) ns
Diffuse 35 (44.9) 21 (28.0) 52 (36.4) 3 (42.9)
ILDc  30 (38.5) 22 (29.3) ns 47 (32.9) 3 (42.9) ns
PAHc  2 (2.7) 5 (6.8) ns 7 (5.0) 0 (0.0) ns
Active ischemic digital ulcersc  7 (9.0) 5 (6.7) ns 9 (6.3) 3 (42.9) .012
Previous ischemic digital ulcersc  28 (35.9) 19 (25.3) ns 41 (28.7) 6 (85.7) .004
Scleroderma renal crisisc  0 (0.0) 1 (1.4) ns 1 (0.7) 0 (0.0) ns
Statinc  9 (11.5) 14 (18.7) ns 20 (14.0) 2 (28.6) ns
(Continues)
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We performed 2 multivariate models (Table 4). The first one con-
sidered all the variables with a P < .1 in univariate analysis (except ESC) 
and showed that older age (P = .001), higher disease severity scores 
(P = .034) and limited cutaneous pattern (P = .001) were significantly 
associated with carotid plaques. The second model considered the 
variables with a P < .1 in the first one with the addition of ESC score 
and diabetes mellitus and confirmed the significance of cutaneous pat-
tern (P = .001) and ESR (P = .010) with only a trend for ESC (P = .074).
3.3 | LL artery involvement
The data were collected in 140 patients. Forty-nine patients (32.9%) 
had plaques at the LL arteries. The artery stenosis was <50% in the 
majority of subjects (32 cases), but 1 patient had a hemodynamically 
significant stenosis between 50% and 60% and 1 between 80% and 
90%. Moreover, occlusion of the anterior tibial artery was found in 
three cases.
We divided LL involvement in proximal or distal accordingly to 
the localization of plaques, that is, proximal (43, 30.7%) or distal (14, 
9.3%) to the popliteal artery.
Patients with proximal LLs were older (P = .007) than patients 
with no plaques, more frequently of male gender (P = .007), with 
higher disease severity score (P = .025) and with a higher preva-
lence of PAH (P = .032) and diabetes (P = .028); in addition they were 
more frequently on statins (P = .014), had lower predicted DLCO 
(P = .044), lower eGFR (P = .005), higher total and LDL cholesterol 
levels (P = .022 and 0.011, respectively), glycemia (P = .037), ESC 
scores (P = .002) and homocysteine (P = .009) (Table 3).
In multivariate analysis, predicted DLCO/AV (P = .004) was found 
lower in patients with plaques, while ESC score was higher (P = .005) 
(Table 4).
Patients with distal LLs were older (P = .049) than patients with 
no plaques, with a higher mRSS (P = .007), with lower HDL cho-
lesterol (P = .018), more often ACA positive (P = .021), with ILD 
(P = .035) and PAH (P = .020) (Table 3).
Multivariate analysis (Table 4) showed that only PAH was 
significantly more frequent in patients with plaques (P = .027 in 
model 1 and P = .006 in model 2), also after correcting for ESC 
and diabetes.
3.4 | UL artery involvement
Only seven patients showed UL plaques. All had ulnar involvement 
and 2 had also radial and humeral plaques. No patients had subcla-
vian involvement. In univariate analysis, patients with plaques had 
worse predicted FVC, DLCO and DLCO/VA (P = .021, .023 and .02, 
respectively), more frequent ulcers (P = .012 for active and P = .004 
for previous), higher disease severity score (P = .043) and were more 
often on anti-endothelin treatment (P = .050) (Table 2).
In multivariate analysis we performed 2 models as previously ex-
plained (Table 4). We preferred previous to active ulcers for the analy-
sis given the bigger sample size in this group. Model 1 showed that only 
a trend for lower predicted FVC and DLCO/VA to be associated with 
UL plaques (P = .066 and P = .078, respectively). In model 2 predicted 
FVC was shown to be significantly associated with plaques (P = .023).
3.5 | Combined analysis
We then analyzed data according to the number of vascular sites in-
volved, that is, carotid and/or proximal LLs and/or distal LLs. We did 
not consider UL involvement since no differences in its prevalence 
were found between patients with and without plaques in other sites. 
Scleroderma patients with carotid plaques more frequently had also 
plaques at the LLs: 37 out of 73 cases (50.7%) vs 12 out of 67 cases 
(17.9%), P < .001. Table 5 summarizes univariate analysis that showed 
both traditional cardiovascular risk factors and disease character-
istics to be associated with an increased number of sites involved. 
When we performed the multivariate analysis only male gender was 
found to be a risk factor for multi-site involvement (data not shown).
 
Carotid plaques Upper limb plaques
No Yes P No Yes P
Hypercholesterolemiac  30 (38.5) 27 (36.0) ns 52 (36.4) 4 (57.1) ns
Blood hypertensionc  7 (9.0) 16 (21.3) .032 22 (15.4) 0 (0.0) ns
Diabetes mellitusc  2 (2.6) 5 (6.7) ns 7 (4.9) 0 (0.0) ns
Abbreviations: ACA, anticentromere antibodies; ANA, antinuclear antibodies; BMI, body mass index; CDK-EPI, Chronic Kidney Disease Epidemiology 
Collaboration; CRP, C-reactive protein; DLCO, diffusion lung for carbon monoxide; eGFR, estimated glomerular filtration rate; ESC, European 
Society of Cardiology; ESR, erythrocyte sedimentation rate; FVC, forced vital capacity; HCQ, hydroxychloroquine; HDL, high density lipoproteins; 
ILD, interstitial lung disease; IMT, intima-media thickness; LDL, low density lipoprotein; mRSS, modified Rodnan skin score; PAH, pulmonary artery 
hypertension; RCS, Raynaud's condition score; VA, alveolar volume; VAS, visual analog scale.
aValues expressed as mean (SD). 
bValues expressed as median (interquartile range). 
cValues expressed as absolute number (%). 
Statistically significant values (P<.05) are indicated in bold.
TA B L E  2   (Continued)
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TA B L E  3   Differences between patients with plaques at lower limb arteries and those without
 
Proximal lower limbs plaques Distal lower limb plaques
No Yes P No Yes P
Agea  53.8 (14.6) 64.5 (12.2) .007 56.9 (21.0) 62.2 (11.0) .049
Disease duration, yb  10 (10) 12 (10) .074 10.0 (11.0) 15.5 (14) ns
BMI, kg/m2a  23.9 (4.2) 24.9 (3.6) ns 23.7 (6.1) 24.4 (8.0) ns
FVC, predicted (%)a  101 (23) 104 (22) ns 102 (26) 101 (29) ns
DLCO, predicted (%)a  70 (21) 61 (19) .044 66 (27) 55 (45) ns
DLCO/AV, predicted (%)a  77 (21) 68 (23) .094 74 (21) 74 (31) ns
mRSSb  7.5 (8.5) 7.0 (6.0) ns 7 (7) 9 (5) .007
Disease severity score, 15b  5 (3) 6 (3) .025 5 (3) 7 (4.5) ns
Creatinine, mg/dLa  0.7 (0.2) 0.8 (0.3) .06 0.7 (0.2) 0.8 (0.2) .044
eGFR using CKD-EPI formula, 
mL/min/1.73 m2a 
91 (19) 79 (18) .005 91 (15) 78 (19) .07
Total cholesterol, mg/dLa  183 (39) 197 (33) .022 188 (34) 187 (37) ns
HDL cholesterol, mg/dLa  58 (20) 60 (28) ns 60 (20) 52 (13) .018
LDL cholesterol, mg/dLa  103 (28) 118 (33) .011 103 (40) 111 (46) ns
Triglycerides, mg/dLa  90 (54) 95 (66) ns 91 (57) 100 (57) ns
Glucose, mg/dLa  83 (12) 89 (16) .037 84 (16) 89 (19) ns
Homocysteine, μmol/La  12.0 (22.8) 16.6 (10.2) .009 11.8 (6.7) 15.9 (11.5) .056
ESR, mm/ha  17 (23) 23 (27) .081 19 (22) 31 (42) ns
CRP, mg/Lb  3 (p) 3 (0) ns 3 (1) 3 (2) ns
ESC scoreb  1 (2) 2 (2) .002 1 (2) 2 (2) ns
Femalec  91 (93.8) 33 (76.7) .007 123 (90.4) 10 (71.4) .056
Smokerc 
Never 65 (67.0) 22 (51.2) ns 83 (61.0) 7 (50.0) ns
Previous 24 (24.7) 15 (34.9) 39 (28.7) 6 (42.9)
Active 8 (8.2) 6 (14.0) 14 (10.3) 1 (7.1)
Endothelin receptor antagonistsc  10 (10.3) 5 (11.6) ns 16 (11.8) 4 (28.6) .095
Iloprost 90 (92.8) 39 (92.9) ns 125 (92.6) 14 (100.0) ns
Current immunosuppressantsc  33 (34.0) 13 (30.2) ns 45 (33.1) 3 (21.4) ns
Previous immunosuppressantsc  39 (40.2) 15 (34.9) ns 53 (39.0) 3 (21.4) ns
HCQc  24 (24.7) 6 (14.0) ns 27 (19.9) 3 (21.4) ns
Current steroid treatment 16 (16.5) 12 (27.9) ns 28 (20.6) 1 (7.1) ns
Autoantibodiesc 
Scl70 40 (41.2) 14 (32.6) ns 54 (39.7) 3 (21.4) .021
ACA 39 (40.2) 22 (51.2) 56 (41.2) 11 (78.6)
ANA 18 (18.6) 7 (16.3) 26 (19.1) 0 (0.0)
Cutaneous patternc 
Limited 58 (59.8) 28 (65.1) ns 84 (61.8) 11 (78.6) ns
Diffuse 39 (40.2) 15 (34.9) 52 (38.2) 3 (21.4)
ILDc  29 (29.9) 16 (37.2) ns 49 (36.0) 1 (7.1) .035
PAHc  1 (1.1) 4 (9.5) .032 4 (3.0) 3 (21.4) .02
Active ischemic digital ulcersc  9 (9.3) 3 (7.0) ns 10 (7.4) 2 (14.3) ns
Previous ischemic digital ulcersc  29 (29.9) 12 (27.9) ns 42 (30.9) 5 (35.7) ns
Scleroderma renal crisisc  1 (1.1) 0. (0.0) ns 1 (0.8) 0 (0.0) ns
Statinc  8 (8.2) 10 (23.3) .014 18 (13.2) 4 (28.6) ns
(Continues)
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In addition, cIMT was higher in patients with proximal and/or dis-
tal LL involvement (0.10 ± 0.04 vs 0.09 ± 0.02, P < .001) and patients 
with a cIMT > 0.09 had 2.6-fold increased risk of having a multi-dis-
trict vasculopathy (95% CI 1.3-5.3, P < .009). No differences in cIMT 
were found for UL involvement.
3.6 | ESC
We studied ESC score to predict cIMT as surrogate of developing ath-
erosclerotic events. A significant correlation between cIMT and ESC 
was found (Spearman's correlation .300, P < .001) and patients with a 
cIMT > 0.09 cm had higher ESC scores (0 ± 2 vs 1 ± 2, P = .002). Indeed, 
ESC score was found to perform fairly in predicting a cIMT > 0.09 cm 
(area under the curve [AUC] 0.646, P = .003) and showed a very low 
sensitivity but a high specificity in identifying patients at high risk, that 
is with an ESC score ≥5% (49.2% and 97.4%, respectively). When con-
sidering an ESC score ≥1% as a marker of increased cIMT, it showed a 
specificity of 53.8% and a sensitivity of 70.5%.
3.7 | Early disease
Patients were divided according to the disease duration, that is 
≤5 years or >5 years. Those with an early disease (39, 25.2%) were sig-
nificantly younger than those with a longstanding disease (46.2 ± 14.0 
vs 61.9 ± 12.5, P < .001). Carotid and distal LL plaques were more 
common in the latter (54.4% vs 33.3%, P = .023, and 12.6% vs 0.0%, 
P = .020, respectively). In contrast, UL and proximal limb plaques were 
as common in early disease patients as in longstanding ones (5%-2% 
vs 2.6%, P = .677 and 32.4% vs. 25.7%, P = .459).
4  | DISCUSSION
In this study we have evaluated the macrovascular involvement in 
patients with SSc by performing a DUS of carotid, UL and LL and 
by collecting information on disease and cardiovascular risk factors 
(CRF). We have found that macrovascular involvement is quite com-
mon and that traditional CRF and some disease characteristics are 
associated with the development of plaques, not only in the univari-
ate analysis that may be affected by age and disease duration, but 
also in multivariate models. In addition, we have confirmed that cIMT 
may be a useful red flag for macrovasculopathy also at LLs. Finally, 
ESC was found to perform fairly also in identifying SSc patients with 
subclinical atherosclerosis.
Table 6 summarizes the most important and recent studies on 
macrovascular involvement in SSc. Prevalence of carotid plaques 
was significantly variable, ranging from 11.8% to 65.5% with our 
study showing results in line with Nordin et al9 and Schiopu et al.18 
Comparing the prevalence of LL and UL involvement is not easy 
given the use of different methods to define these manifestations. It 
is worth noticing that, although the prevalence of plaques is not un-
common, only a small proportion of patients had hemodynamically 
significant stenosis.
In our cohort we found that carotid and LL involvement is quite 
common and that, in multivariate analysis, traditional CRF are im-
portant determinants of proximal LL atherosclerosis with a trend for 
carotid and distal LL involvement. Similar results, although with a 
less complete evaluation of traditional CRF, have been reported in 
other studies.11,19,20 Traditional CRF may play a role in macrovascu-
lopathy, especially at proximal LLs, also in SSc, so the rheumatologist 
should always assess cardiovascular risk in these patients in order to 
prevent the development of its possible complications. When treat-
ing cardiovascular risk in SSc the rheumatologist should keep in mind 
there is some evidence that statins, apart from lowering blood cho-
lesterol, may have favorable effects also on the fibrotic and vascular 
mechanisms involved in SSc pathogenesis.21
In addition, ESR was found to be higher in patients with carotid 
plaques. There is strong evidence that inflammation increases the 
risk of atherosclerosis not only in the general population,22 but also 
in SSc patients.18 In particular, Ozen et al19 and Sedky et al20 have 
recently found an increase in ESR in SSc patients with subclinical 
atherosclerosis. Although ESR is more variable than CRP in assessing 
 
Proximal lower limbs plaques Distal lower limb plaques
No Yes P No Yes P
Hypercholesterolemiac  35 (36.1) 15 (34.9) ns 49 (36.0) 7 (50.0) ns
Blood hypertensionc  13 (13.4) 9 (20.9) ns 20 (14.7) 2 (14.3) ns
Diabetes mellitusc  2 (2.1) 5 (11.6) .028 6 (4.4) 1 (7.1) ns
Abbreviations: ACA, anticentromere antibodies; ANA, antinuclear antibodies; BMI, body mass index; CDK-EPI, Chronic Kidney Disease Epidemiology 
Collaboration; CRP, C-reactive protein; DLCO, diffusion lung for carbon monoxide; eGFR, estimated glomerular filtration rate; ESC, European 
Society of Cardiology; ESR, erythrocyte sedimentation rate; FVC, forced vital capacity; HCQ, hydroxychloroquine; HDL, high density lipoproteins; 
ILD, interstitial lung disease; IMT, intima-media thickness; LDL, low density lipoprotein; mRSS, modified Rodnan skin score; PAH, pulmonary artery 
hypertension; RCS, Raynaud's condition score; VA, alveolar volume; VAS, visual analog scale.
aValues expressed as mean (SD). 
bValues expressed as median (interquartile range). 
cValues expressed as absolute number (%). 
Statistically significant values (P<.05) are indicated in bold.
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TA B L E  4   Multivariate analysis of possible determinants of plaques
Carotid  B Wald Significance Exp(B)
95% CI for Exp(B)
Inferior Superior
Model 1 Age 0.148 10.604 .001 1.16 1.061 1.268
Disease severity score (15) 0.284 4.488 .034 1.328 1.021 1.726
eGFR 0.023 1.517 .218 1.024 0.986 1.063
Glucose (mg/dL) 0.019 0.571 .450 1.019 0.971 1.069
ESR (mm/h) 0.043 3.564 .059 1.044 0.998 1.091
Homocysteine (μmol/L) −0.036 0.768 .381 0.965 0.89 1.046
Female gender −1.246 2.201 .138 0.288 0.055 1.492
Cutaneous pattern (limited) 2.514 11.654 .001 12.35 2.917 52.294
Blood hypertension 0.328 0.166 .684 1.388 0.286 6.734
ESC 0.302 3.194 .074 1.353 0.971 1.884
Diabetes mellitus 0.476 0.24 .624 1.609 0.24 10.766
ESR (mm/h) 0.038 6.642 .010 1.039 1.009 1.069
Cutaneous pattern (limited) 1.456 10.587 .001 4.290 1.784 10.314
Disease severity score (15) 0.124 2.298 .130 1.132 0.964 1.328
Model 1 PAH −1.401 1.502 .351 0.246 0.013 4.683
Statin −0.595 0.737 .420 0.552 0.130 2.338
Diabetes mellitus −1.413 1.109 .203 0.243 0.028 2.139
Female gender −1.942 0.989 .050 0.143 0.021 0.997
Age 0.064 0.037 .083 1.066 0.992 1.146
DLCO/AV (predicted, %) −0.039 0.019 .040 0.961 0.926 0.998
Creatinine (mg/dL) 0.219 1.524 .886 1.245 0.063 24.697
LDL cholesterol 0.011 0.009 .243 1.011 0.993 1.030
Glucose (mg/dL) −0.001 0.028 .977 0.999 0.946 1.056
Homocysteine (μmol/L) 0.040 0.044 .359 1.041 0.955 1.135
ESR (mm/h) 0.023 0.019 .224 1.024 0.986 1.063
Disease severity score (15) −0.070 0.145 .629 0.932 0.702 1.239
ESC 0.474 7.900 .005 1.606 1.154 2.234
Diabetes mellitus −1.626 3.196 .074 0.197 0.033 1.170
DLCO/AV (predicted, %) −0.028 8.080 .004 0.972 0.954 0.991
Model 1 Age −0.033 0.367 .544 0.968 0.870 1.076
Disease duration −0.099 1.161 .281 0.906 0.756 1.085
mRSS 0.121 0.715 .398 1.129 0.852 1.495
eGFR −0.039 1.491 .222 0.961 0.902 1.024
HDL cholesterol (mg/dL) −0.055 1.777 .182 0.947 0.873 1.026
ESR (mm/h) −0.003 0.006 .939 0.997 0.927 1.072
Homocysteine (μmol/L) 0.077 2.479 .115 1.080 0.981 1.189
Female gender −0.566 0.272 .602 0.568 0.068 4.762
Endothelin receptor antagonists 0.012 0.000 .995 1.012 0.032 31.708
Autoantibodies −0.789 0.534 .465 0.454 0.055 3.770
ILD 20.279 0.000 .998 6.413 × 108 0.000 –
PAH 4.237 4.900 .027 71.429 1.623 –
Model 2 ESC 0.370 2.926 .087 1.448 0.947 2.213
Diabetes mellitus −0.248 0.045 .833 0.780 0.078 7.800
PAH 2.422 7.486 .006 11.264 1.988 63.832
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inflammation and may be affected by many factors, such as age and 
gender, our result was confirmed also after correcting for them, so 
its increase in vasculopathy patients may be actually related to the 
role of inflammation in atherosclerosis.
Some disease characteristics have been found to increase the 
risk of macrovascular involvement independently from traditional 
CRF. Subjects with limited pattern were shown to have an increased 
risk of carotid plaques. Nordin et al9 has previously reported a simi-
lar result for anti-centromere antibodies after correction for gender, 
age and disease duration. These antibodies have been found to be 
also associated with a lower ABPI.23 Although in our cohort ACAs 
were showed to be more frequent in patients with carotid plaques 
only in univariate analysis, our results on limited pattern seems to 
support that those patients with a more pronounced microvascular 
than fibrotic process have an increased risk of carotid atheroscle-
rosis, supporting a possible link between micro- and macrovascular 
involvement. On the other hand, one may argue that patients with a 
diffuse pattern or anti-Scl70 antibody positivity are more often on 
immunosuppressive drugs; it is worth noticing that, in our cohort, 
this treatment was found to be protective against carotid plaques in 
univariate analysis. Although the role of inflammation in atheroscle-
rosis is well known, there is still a lack of data on the possible role of 
immunotherapy to prevent its progression.24 We speculate that the 
higher prevalence of carotid plaques in limited SSc may be related 
to different factors, such as a possible role of microvascular damage 
or a less frequent use of immunosuppressive treatment, although 
other factors, such as other treatments or the degree of inflamma-
tion, cannot be ruled out and further studies are needed. Also, for 
proximal and distal LLs a possible link with microvasculopathy could 
be hypothesized. Indeed, low DLCO/AV and PAH, both markers of 
microvascular disease, were more frequent in patients with proximal 
or distal LL involvement. No data in the literature are available for 
a proper comparison since different methodologies were used to 
assess LL arteriopathy. Nevertheless, SSc patients were reported to 
have an increased risk of vasculopathy in 2 out 3 studies present in 
the literature. Again, Nordin et al9 have found that ACA + patients 
suffered more often from ischemic peripheral vascular disease de-
fined as intermittent claudication + ankle-brachial index (ABI) <0.9 
or peripheral arterial thrombosis/embolus (confirmed by angiogram 
or Doppler flow studies). ACAs are a well-known risk factor for PAH 
but no analysis on this were reported probably because of the small 
number of patients with both or either of these characteristics. In ad-
dition, Ozen et al19 have recently found that PAH was more common 
in patients with increased cIMT, further supporting a possible link 
between micro- and macrovasculopathy via a common pathologic 
pathway such as endothelial dysfunction.25,26 Although these data 
support an intriguing link between micro- and macrovasculopathy, 
there is contrasting evidence on videocapillaroscopy. It was found 
to be related to ulnar involvement by Lescoat et al27 while Schioppo 
et al28 found no correlation. It is worth noticing that these vessels 
are not a usual target of atherosclerosis and do not clearly reflect 
large vessel involvement, so further studies are needed to clarify 
this issue. Indeed, also in our study, traditional risk factors were not 
found to be independently associated with UL involvement. This 
could be expected since ulnar involvement is an unusual finding in 
atherosclerosis, whereas it may be a possible peculiar manifesta-
tion of SSc given its high prevalence,10,29 as partially supported by 
significantly higher disease severity scores in patients with plaques 
in univariate analysis. In our experience the involvement of UL ar-
teries was observed in a very little subgroup of patients, different 
from the results previously reported in other studies.10,29 Although 
our data showed that ulnar vasculopathy is a risk factor for digital 
ulcers only in univariate analysis, that may be affected by disease 
duration, this may further support other previous studies since the 
lack of significance in multivariate analysis may be caused by both 
the small number of patients with UL vasculopathy and the correla-
tion between disease severity score and ulcers (actually when we 
re-run the analysis without Medsger score, ulcers showed statistical 
Carotid  B Wald Significance Exp(B)
95% CI for Exp(B)
Inferior Superior
Model 1 FVC (predicted, %) −0.101 3.371 .066 0.904 0.811 1.007
Previous ischemic digital ulcers 18.813 0.000 .995 1.4 × 108 0.000 –
DLCO/AV (predicted, %) −0.092 3.105 .078 0.912 0.823 1.010
Endothelin receptor antagonists 4.142 1.541 .215 62.903 0.091 4.353 × 104
Disease severity score (15) 0.125 0.272 .602 1.134 0.708 1.815
Model 2 ESC −0.592 0.940 .332 0.553 0.167 1.830
Diabetes mellitus 17.152 0.000 .999 2.8 × 1010 0.000 –
FVC (predicted, %) −0.049 5.181 .023 0.952 0.912 0.993
DLCO/AV (predicted, %) −0.039 3.261 .071 0.962 0.922 1.003
Abbreviations: DLCO, diffusion lung for carbon monoxide; eGFR, estimated glomerular filtration rate; ESC, European Society of Cardiology; 
ESR, erythrocyte sedimentation rate; FVC, forced vital capacity; HDL, high density lipoproteins; ILD, interstitial lung disease; LDL, low density 
lipoproteins; mRSS, modified Rodnan skin score; PAH, pulmonary artery hypertension; VA, alveolar volume; VAS, visual analog scale.
Statistically significant values (P<.05) are indicated in bold.
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significance). Indeed, both our group and other authors previously 
reported a positive association between necrosis at LL extremities 
and concomitant peripheral artery disease30,31; together these data 
suggest that a concomitant micro- and macrovascular involvement 
may favor the development of ischemic complications in SSc. To the 
best of our knowledge, the link between reduced FVC and ulnar 
plaques is a finding not previously reported. A possible explana-
tion is that the fibrotic process may be also involved in ulnar artery 
involvement.
Interesting is the result that patients with early disease do not 
seem to have a lower risk of UL and proximal LL plaques than pa-
tients with a longer disease, although they are at a significantly 
younger age. We think more studies are needed to confirm this data 
that may further shed a light upon a possible role of SSc itself in 
causing macrovascular involvement.
We have confirmed that carotid atherosclerosis increases the 
risk of LL involvement. In particular, a cIMT > 0.09 gives a more than 
2.6-fold increased risk of having plaques at the LLs. Given the high 
prevalence of macrovasculopathy in SSc patients, these data further 
stress the importance of performing a wide evaluation involving not 
only a carotid DUS but also of other sites.
Finally, ESC was found to fairly predict subclinical atherosclero-
sis with AUC of 0.646. This result differs from that reported by Ozen 
et al19 who showed a poor performance of different cardiovascular 
TA B L E  5   Differences between patients with 0 or 1 site with 
plaques and those with 2 or 3 sites involved
  
Sites with plaques
P0 or 1 2 or 3
Agea   53.9 (14.3) 66.1 (11.9) <.001
Disease duration, yb   10 (10) 12 (10) .094
BMI, kg/m2a   23.9 (4.1) 25.1 (3.9) ns
FVC, predicted (%)a   102 (21) 102 (26) ns
DLCO, predicted (%)a   69 (20) 61 (22) .046
DLCO/AV, predicted 
(%)a 
 76 (20) 69 (26) ns
mRSSb   8 (7) 8 (7) ns
Disease severity score, 
15b 
 5 (3) 6 (3) .023




 91 (19) 79 (18) .007
Total cholesterol, mg/
dLa 
 185 (34) 191 (34) ns
HDL cholesterol, mg/
dLa 
 60 (19) 61 (15) ns
LDL cholesterol, mg/
dLa 
 106 (28) 113 (34) ns
Triglycerides, mg/dLa   99 (47) 110 (47) ns
Glucose, mg/dLa   83 (12) 91 (16) .001
Homocysteine, μmol/La   13.7 (6.6) 18.4 
(10.3)
.007
ESR, mm/ha   17 (23) 24 (30) .038
CRP, mg/Lb   3 (0) 3 (0) ns
ESC scoreb   0 (2) 2 (1) <.001
Femalec  F 97 (94.2) 27 (73.0) <.001
Smokerc  Never 68 (66.0) 19 (51.4) ns
Previous 26 (25.2) 13 (35.1) ns
Active 9 (8.7) 5 (13.5) ns
Endothelin receptor 
antagonistsc 
 9 (8.7) 6 (16.2) ns
Iloprost  94 (92.2) 35 (94.6) ns
Current 
immunosuppressantsc 
 36 (35.0) 10 (27.0) ns
Previous 
immunosuppressantsc 
 43 (41.7) 11 (29.7) ns
HCQc   25 (24.3) 5 (13.5) ns
Current steroid 
treatment
 19 (18.4) 9 (24.3) ns
Autoantibodiesc  Scl70 45 (43.7) 9 (24.3) .060
ACA 39 (37.9) 22 (59.5)
ANA 19 (18.4) 6 (16.2)
Cutaneous patternc  Limited 60 (58.3) 26 (70.3) ns




P0 or 1 2 or 3
ILDc  0 33 (32.0) 12 (32.4) ns
PAHc  0 0 (0.0) 5 (13.9) <.001
Active ischemic digital 
ulcersc 
0 8 (7.8) 4 (10.8) ns
Previous ischemic 
digital ulcersc 
0 32 (31.1) 9 (24.3) ns
Scleroderma renal 
crisisc 
0 1 (1.0) 0 (0.0) ns
Statinc  0 9 (8.7) 9 (24.3) .015
Hypercholesterolemiac  0 39 (37.9) 11 (29.7) ns
Blood hypertensionc  0 14. (13.6) 8 (21.6) ns
Diabetes mellitusc  0 3 (2.9) 4 (10.8) .059
Abbreviations: ACA, anticentromere antibodies; ANA, antinuclear 
antibodies; BMI, body mass index; CDK-EPI, Chronic Kidney Disease 
Epidemiology Collaboration; CRP, C-reactive protein; DLCO, diffusion 
lung for carbon monoxide; eGFR, estimated glomerular filtration rate; 
ESC, European Society of Cardiology; ESR, erythrocyte sedimentation 
rate; FVC, forced vital capacity; HCQ, hydroxychloroquine; HDL, high 
density lipoproteins; ILD, interstitial lung disease; IMT, intima-media 
thickness; LDL, low density lipoprotein; mRSS, modified Rodnan skin 
score; PAH, pulmonary artery hypertension; RCS, Raynaud's condition 
score; VA, alveolar volume; VAS, visual analog scale.
aValues expressed as mean (SD). 
bValues expressed as median (interquartile range). 
cValues expressed as absolute number (%). 
Statistically significant values (P<.05) are indicated in bold.
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risk scores in SSc patients. This difference may be explained by the 
significantly lower cIMT and prevalence of carotid plaques in their 
cohort as compared to our population.
Given that atherosclerosis is quite common also in SSc patients 
and that carotid DUS is a good screening tool, since cIMT correlates 
well with both ESC score and macrovasculopathy in other sites, our 
study further stresses that a thorough cardiovascular screening of 
SSc patients may be effective and very important in particular if we 
consider that peripheral atherosclerosis is a well-known risk factor 
for cardiovascular events in the general population and statins and 
aspirin are recommended in its treatment.32 In addition, cardiovas-
cular events accounted for about 29% of non-SSc-related deaths in 
the large EUSTAR cohort,33 so its prevention is an issue also in SSc.
In conclusion, this study shows that macrovascular involvement is 
quite common in SSc patients and that, apart from a possible role of 
traditional risk factors, some disease characteristics are significantly 
associated with atherosclerotic plaques. In addition, we further under-
line the importance of screening for macrovascular involvement at LLs 
in those SSc patients with an increased cIMT. Finally, ESC score was 
found to have a fair performance in predicting subclinical atheroscle-
rosis also in SSc patients. Our study suggests that a complete evalua-
tion of patients is mandatory for rheumatologists for a comprehensive 
approach to this disease, that is still without a specific treatment, and a 
multidisciplinary and tailored therapy may allow longer survival.
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